Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing oral small molecule degrader medicines for immunological diseases, will report its second quarter 2026 financial results on August 5, 2026. The announcement marks a key update for investors tracking the company’s progress in targeted protein degradation (TPD), a therapeutic approach aimed at addressing disease targets inaccessible with conventional treatments. The results will provide insight into the firm’s operational performance and pipeline development during the period.

To discuss the financial results, Kymera Therapeutics will host a video conference call and webcast at 8:30 a.m. ET on August 5, 2026. The event allows stakeholders to review the quarterly performance directly with management. A replay of the webcast will be archived and available following the event for those unable to attend live.

Event Access Details

Investors and analysts can join the video call or view the livestreamed webcast by registering via the provided link or visiting the "News and Events" section in the Investors area of the company’s website at www.kymeratx.com . The registration process ensures secure access to the broadcast.

Company Background

Founded in 2016, Kymera Therapeutics is pioneering the field of targeted protein degradation to develop medicines that address critical health problems. The company has advanced the first degrader into the clinic for immunological diseases and is focused on building an industry-leading pipeline of oral small molecule degraders. These therapies aim to provide a new generation of convenient and highly effective treatments for patients with these conditions. Kymera has been recognized as one of Boston’s top workplaces for the past several years.

Contact Information

For investor inquiries, Justine Koenigsberg can be reached at investors@kymeratx.com or 857-285-5300. Media inquiries should be directed to Matthew Henson at media@kymeratx.com or 857-285-5300.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) appointed Terence Rooney, MD, as Chief Medical Officer on July 27, 2026, to lead global clinical development strategy for its oral immunology portfolio. The appointment addresses the leadership transition following the retirement of Jared Gollob, MD, who served in the role for eight years. This change positions the clinical-stage biopharmaceutical company to advance its targeted protein degradation medicines across multiple immuno-inflammatory diseases during a period of expanding pipeline momentum.

Dr. Gollob will retire from his executive position but will remain with Kymera Therapeutics as an advisor through the end of the year. Nello Mainolfi, PhD, Founder, President and CEO of Kymera Therapeutics, stated that Dr. Gollob helped shape the company’s development strategy and infrastructure from its earliest days. Mainolfi emphasized that Dr. Rooney’s broad development experience and physician-scientist perspective make him suited to realize the potential of the company’s pipeline.

Leadership Background

Dr. Rooney brings extensive experience in immunology drug development from previous roles at Johnson & Johnson, Eli Lilly, and Roche. At Johnson & Johnson, he served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, where he led global compound development teams and portfolio strategy. His career spans small molecules, peptides, biologics, and cell therapies across dermatology, respiratory, rheumatology, gastroenterology, and rare diseases.

Dr. Rooney contributed to successful marketing applications for medicines including ICOTYDE, IMAAVY, OLUMIANT, STELARA, and TREMFYA. He received his medical degrees from the Royal College of Surgeons in Ireland and completed training at Dublin Academic Teaching Hospitals and the University of California, San Francisco.

Strategic Outlook

Dr. Rooney cited significant treatment gaps for patients with chronic immunological conditions as a primary motivation for joining Kymera Therapeutics. He highlighted the company’s depth of science and execution across its diverse portfolio as key factors in the decision. In his new role, he will guide the advancement of oral treatment options for multiple diseases, aiming to improve patient outcomes globally. Mainolfi noted that the appointment coincides with tremendous momentum for the company, with multiple clinical programs advancing and an early innovation engine rooted in bold science.